Replies to post #2304 on BioPharmX Corp fka BPMX

[Whos_Who]

In November 2018, the company reduced its operating costs by executing a 33% reduction in workforce and discontinuing non-core development programs. As part of this more focused strategy, the company divested its molecular iodine technology, including the dietary supplement product, VI2OLET, thereby allowing the company to focus on its dermatology product candidates.

So your a bit caught up...

https://www.prnewswire.com/news-releases/biopharmx-reports-third-quarter-2019-financial-results-300761396.html